We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alpine Immune Sciences, Inc. (ALPN - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alpine Immune Sciences, Inc. is one of 1087 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Alpine Immune Sciences, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPN's full-year earnings has moved 14.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALPN has returned 105% so far this year. Meanwhile, stocks in the Medical group have lost about 8.2% on average. This shows that Alpine Immune Sciences, Inc. is outperforming its peers so far this year.
Novo Nordisk (NVO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 49.9%.
For Novo Nordisk, the consensus EPS estimate for the current year has increased 0.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Alpine Immune Sciences, Inc. belongs to the Medical - Drugs industry, a group that includes 192 individual stocks and currently sits at #62 in the Zacks Industry Rank. Stocks in this group have lost about 12.6% so far this year, so ALPN is performing better this group in terms of year-to-date returns.
Novo Nordisk, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 11-stock industry is ranked #81. The industry has moved +6.6% so far this year.
Alpine Immune Sciences, Inc. and Novo Nordisk could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Alpine Immune Sciences, Inc. (ALPN - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alpine Immune Sciences, Inc. is one of 1087 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Alpine Immune Sciences, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPN's full-year earnings has moved 14.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALPN has returned 105% so far this year. Meanwhile, stocks in the Medical group have lost about 8.2% on average. This shows that Alpine Immune Sciences, Inc. is outperforming its peers so far this year.
Novo Nordisk (NVO - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 49.9%.
For Novo Nordisk, the consensus EPS estimate for the current year has increased 0.8% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Alpine Immune Sciences, Inc. belongs to the Medical - Drugs industry, a group that includes 192 individual stocks and currently sits at #62 in the Zacks Industry Rank. Stocks in this group have lost about 12.6% so far this year, so ALPN is performing better this group in terms of year-to-date returns.
Novo Nordisk, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 11-stock industry is ranked #81. The industry has moved +6.6% so far this year.
Alpine Immune Sciences, Inc. and Novo Nordisk could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.